spacer
home > pmps > spring 2017 > open and close
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Open and Close

For packaging to be child-resistant, it must be difficult for a child under the age of four years and four months (52 months) to open or gain access to the contents in a reasonable period – but not challenging for an adult up to 70 years old to use properly. This is the generally accepted definition, and is used in international and European standards as well as the Code of Federal Regulations (CFR) in the US (it is worth noting at this point that child-resistant packaging is not ‘child-proof’).

Child-resistant reclosable packs were first introduced in the UK in the mid- 1970s as an American import and have achieved increasing acceptance in the UK and other EU member states over the past 40 years. In Britain, non-reclosable child-resistant packs were slow to emerge and were only standardised in 2001. As well as being subject to international, European and American standards, the use of child-resistant packs for certain products has been set out in various regulations, including the Human Medicines Regulations 2012 and the globally harmonised system of classification and labelling chemicals, which came into full force in 2015.

Since its introduction, this type of packaging has been improved and made more effective, not only in levels of resistance to opening by children but in its ease-of-use by adults. In addition, increasing and ongoing efforts have been made to create more lightweight packaging across the board.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Stephen Wilkins was appointed Chief Executive Officer of the Child-Safe Packaging Group upon its formation in 1995 and has driven its activities since then. In addition, he is Director of Davies Development and Testing and sits on a number of BSI and ISO committees concerned with developing standards for packaging. Stephen attended the University of Durham Business School, UK, where he obtained a Master’s degree in Business Administration.
spacer
Stephen Wilkins
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioIVT Acquires Optivia Biotechnology, Adding Transporter Assay Products and Services to its ADME-Tox Portfolio

BioIVT, a leading provider of research models and services for drug development, today announced that it has acquired Santa Clara, CA-based Optivia Biotechnology and its comprehensive portfolio of transporter assays, multi-transporter models, transporter systems biology, and molecular transport research solutions.
More info >>

White Papers

Device Develop for Combo Products

Phillips-Medisize

Combination products are defined as therapeutics combining two or more products (drug/device, biologics/device, biologics/drugs or drug/device/biologics), regulated and sold as a single unit. As these pharmaceutical and biological therapies and treatments have evolved, so has the need to develop appropriate delivery mechanisms for these applications. When developing a combination product, there are many things that need to be considered – the critical relationships between device development and the pharmaceutical or biologic, early establishment of regulatory and clinical strategies, understanding ‘user’ needs, determining product requirements, as well as, device manufacturing variation.
More info >>

 
Industry Events

4th Annual Genome Editing Congress

8-9 November 2018, London, UK

Oxford Global is proud to present its 4thAnnual Genome Editing Congress taking place on 8-9 November 2018 in London. As part of our Genomics and Synthetic Biology UK series, our congress will bring together Over 600 delegates representing internationally renowned research & academic institutions, clinical research institutions and pharmaceutical companies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement